Stocksigma LogoStocksigma Logo

Lord’s Mark Advances Breast Cancer Screening Tech to Final Trials

Lord’s Mark Industries received Technical Committee approval to advance its AI-powered, radiation-free wearable breast cancer screening technology to final

Lord’s Mark Advances Breast Cancer Screening Tech to Final Trials

Lords Mark Industries Ltd · Others (Uncategorized) · 23 Sept 2026, 2:03 pm

Lord’s Mark Advances Breast Cancer Screening Tech to Final Trials Lord’s Mark Industries received Technical Committee approval to advance its AI-powered, radiation-free wearable breast cancer screening technology to final clinical trials across the US, Great Britain, and Europe, following completed India trials. Phase 2 trials targeting 98% accuracy will commence in Jan'27. Holding exclusive commercialisation rights in collaboration with C-MET, the company is pursuing CDSCO, US FDA, and European approvals. It targets trial completion by Mar'27 and a commercial launch by Apr'27, addressing a global breast cancer diagnostics market projected to reach USD 11.4B by 2033 (8.8% CAGR).

Original exchange filing (PDF)

More announcements from Lords Mark Industries Ltd

All Lords Mark Industries Ltd announcements